For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...

By using CRISPR/Cas9 to engineer cells from healthy donors, AVC-203 is designed to circumvent graft-versus-host disease and host-mediated rejection.

Scientists are laying the groundwork for treating one of the most common genetic conditions in humans. Research out today ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...

The ACC has published a scientific statement regarding the use of gene editing therapy for cardiovascular disease.